Allylestrenolによる前立腺肥大症の治療

Abstract

Fifteen patients with BPH received a progestational agent, allylestrenol (Gestanon) daily for periods ranging to at least 3 months or more. Dysuria, being complained by 12 patients, was judged to have disappeared in 8 patients, lessened in 2 and remained unchanged in 2. Of 11 patients with complaint of frequent urination, 6 patients returned to normal frequency and 3 showed a decrease of frequency. Residual urine volumes decreased in 13 of 15 patients beginning one to two months after start of therapy and increased in 2. Reduction in size of the prostate as measured by the cystourethrogram was seen in 5 of 11 patients. But in all the patients, no remarkable change in size of the gland was noted under rectal examination. Biopsy specimen for histological examination was successfully obtained before and after allylestrenol administration in 4 patients. Flattening of epithelial projection into the lumen, dilatation of acini and decrease in epithelial cell heights were demonstrated in 2 of 4 patients. Any detectable side-effect was not noted except one patient with slightly elevated GOT and GPT.